All certificates of analysisTirzepatide 60mg product page

Tirzepatide 60mg

Results reported for the submitted sample

Tirzepatide 60mg

Lot in our record: TIR-20260811-01
Certificate ID: COA7921
Lot printed on the certificate: TIR-20260811-01

Bioviridian Inc. · COA7921

Reported identity: Tirzepatide; LC-MS/MS
Measured content / assay: 61.23 mg; HPLC Quantitation
Chromatographic purity: 99.86%; RP-HPLC (214 nm)

Testing scope

Results are reported for the submitted sample. They do not establish the identity or composition of every vial carrying a lot label.

We have not commissioned sterility or endotoxin testing for this material. This is the owner's statement about Purely Peptides' commissioning, not a claim about testing by upstream parties.

This report does not include a residual-solvent result.

These results do not establish suitability for human or veterinary use.

Independent issuer confirmation has not been recorded for this assessment. A hosted PDF or report code does not establish authenticity or physical-sample linkage.

Additional laboratory results (2)

Krause Analytical LLC · sample 59abg6p · Lab #214172

Tested by Krause Analytical LLC; commissioned through Finnrick.

The certificate’s Batch/Lot field shows the Finnrick sample code 59abg6p. We list this result under lot TIR-20260811-01.

Chromatographic purity: >99.9%; Method: HPLC-UV/MS
Measured content: 63.6 mg; Method: HPLC-UV-MS
Identity (mass spectral match): ID Confirmed; Method: HPLC-UV-MS
Label claim: 60 mg
% of label, as printed: 106.0
COC#: 145871
Received: 2026-09-18
Analyzed: 2026-09-24
Report issued: 2026-10-01
Laboratory address: 8127 Mesa Drive Suite B-206, Austin, TX 78759
Laboratory director: Mark C. Krause
PDF SHA-256: 8b2661825c8ae4ea405746eca21d5705db3a52e145376b26963a4a789961218e

Original full certificate (PDF) · 59abg6p

Krause Analytical LLC · sample fwpftwh · Lab #214173

Tested by Krause Analytical LLC; commissioned through Finnrick.

The certificate’s Batch/Lot field shows the Finnrick sample code fwpftwh. We list this result under lot TIR-20260811-01.

Chromatographic purity: >99.9%; Method: HPLC-UV/MS
Measured content: 60.5 mg; Method: HPLC-UV-MS
Identity (mass spectral match): ID Confirmed; Method: HPLC-UV-MS
Label claim: 60 mg
% of label, as printed: 100.9
COC#: 145871
Received: 2026-09-18
Analyzed: 2026-09-24
Report issued: 2026-10-01
Laboratory address: 8127 Mesa Drive Suite B-206, Austin, TX 78759
Laboratory director: Mark C. Krause
PDF SHA-256: 49d92f213eb97864bcebb5c932e0325ceb56616fefdd97eeb34144ca7d885af7

Original full certificate (PDF) · fwpftwh

Original certificate (PDF)Read about analytical terms

Issuer and report details

Bioviridian Inc. is named on the certificate as the issuing laboratory. Independent issuer confirmation has not been recorded for this assessment (not checked).

Check the report with the issuing laboratory

Use certificate ID COA7921. Issuer confirmation would not by itself establish all-vial or physical-sample linkage.

Methods, reporting context and disclosure provenance

Sample type: White lyophilized powder
Molecular weight (g/mol), as recorded: 4813.5
Sample received: 2026-08-18
Report issued: 2026-08-23
HPLC retention time, as recorded: 11.913 min

Results and methods retain the report record's original units and precision. A result here is not a finding that an acceptance specification was met.

Source: page 1, Test Results, Sample Information and Analytical Methods. Document annotations were visually inspected on 2026-10-10; no new laboratory authentication has been performed.

Commissioning disclosure: Purely Peptides owner's statement in the editorial and batch-results brief, bound to this inspected report and material. It is separate from document-derived absence of a residual-solvent result.

Published by Purely Peptides, a commercial research-material supplier. These documentation pages do not establish suitability for human or veterinary use.